Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIDEA.L Regulatory News (IDEA)

  • There is currently no data for IDEA

Board Changes

1 Jul 2020 07:00

RNS Number : 6223R
Ideagen PLC
01 July 2020
 

July 1st 2020

 

 

Ideagen PLC

("Ideagen" "the Company" or "the Group")

 

Board Change

 

Ideagen PLC (AIM: IDEA), a leading supplier of integrated risk management software to highly regulated industries, is pleased to confirm that Emma Hayes has today joined the Group as Chief Financial Officer, succeeding Graeme Spenceley, as announced on 7th January 2020.

 

Graeme has retired as a Director but will remain with the Group as Company Secretary and financial advisor to the Board. This role will be on a full-time basis until 31 October 2020 which will provide for a full and effective handover to Emma, and thereafter he will continue in that capacity on a part-time basis.

 

Emma was previously Group Finance Director, Capital Delivery and Commercial, at Severn Trent PLC having held the position since 2017. In this role she controlled a P&L and Balance Sheet of approximately ÂŁ600m and was responsible for driving operational efficiencies through her 100-strong team. Before that Emma spent 10 years with Deloitte LLP as a Corporate Finance Director where she led origination and execution of a wide range of M&A transactions. Emma qualified as a Chartered Accountant (ACA) with BDO.

Graeme Spenceley was previously awarded 750,000 share options under the Company's 2018 LTIP scheme (as announced on 29 March 2019 with details of the relevant scheme announced on 23 October 2018). The Board and Graeme have agreed that this award will be reduced to 187,500 options and that these will vest in full on the achievement of the first performance criteria (being the Company's share price reaching 196 pence over 30 consecutive business days).

Emma has in turn been awarded 562,500 share options under the 2018 LTIP with the same vesting conditions such that 187,500 of these options becoming eligible to vest on the first performance criterion described above being met, with the remainder becoming eligible to vest on the Company's share price reaching 259 pence over 30 consecutive business days. All other terms and conditions relating to the 2018 LTIP as previously described apply equally.

 

Ben Dorks, Chief Executive of Ideagen, commented; "Firstly, the Board would like thank Graeme for his outstanding commitment to Ideagen. His insight, acumen and support over the past 10 years has been invaluable and it has been a great pleasure to work alongside him. We are pleased that Graeme will remain with the business as Company Secretary which will provide for a robust transition.

 

The Board is delighted to welcome Emma to the Group who brings with her a deep understanding of both financial structures and processes and M&A. We will benefit hugely from Emma's experience and ability as Ideagen continues to execute its global growth strategy.''

 

There are no further disclosures to be made in relation to Emma Jane Hayes, aged 39, pursuant to Schedule 2(g) of the AIM Rules for Companies. .

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (MAR).

 

Enquiries:

Ideagen plc

01629 699100

David Hornsby, Executive Chairman

 

Ben Dorks, Chief Executive Officer

 

Graeme Spenceley, Chief Financial Officer

 

 

 

 finnCap Limited

020 7220 0500

Henrik Persson/James Thompson/ Hannah Boros (Nomad)

 

Alice Lane (ECM)

 

 

Canaccord Genuity Limited

 020 7523 8000

Simon Bridges

 

Richard Andrews

 

 

 

About Ideagen plc

Ideagen is a UK-headquartered, global technology company quoted on the London Stock Exchange AIM market (Ticker: IDEA.L).

The Group provides IRM software and services to organisations operating within highly regulated industries such as aviation, banking and finance and life science, with its main operational premises spread throughout the UK, EU, US, Middle East and SE Asia.

With an excellent portfolio of software products including Q-Pulse, Coruson, Pentana Audit and PleaseReview, Ideagen helps its clients reduce costs, improve operational efficiency, strengthen compliance and oversight and anticipate and manage every detail of risk.

Currently, more than 4,700 organisations use Ideagen's products including seven of the top 10 UK accounting firms, all of the top aerospace and defence companies and 75% of the world's leading pharmaceutical firms.

Ideagen's diverse and varied customer base includes many well-known, global brands such as British Airways, Aggreko, BAE, Ryanair, US Navy, KLM, BBVA, Bank of New York, Commerzbank, Meggitt, Heineken, Johnson Matthey, Haeco Group and European Central Bank. As well as this, Ideagen counts 180 hospitals across the UK and US amongst its client base.

For further information please visit www.ideagen.com

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

Name:

Emma Hayes

2.

Reason for the notification

a)

Position/status:

Chief Financial Officer

b)

Initial notification/Amendment:

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:

Ideagen plc

 

b)

LEI:

213800KS1MLITOVNYC85

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument:

Identification code:

Ordinary shares of 0.1p

 

GB00B0CM0C50

b)

Nature of the transaction:

Grant of LTIPs over Ordinary Shares

c)

Price(s) and volume(s):

Price(s)

Volume(s)

n/a

562,500

 

d)

Aggregated information:

· Aggregated volume:

· Price:

See 4 (c) above

e)

Date of the transaction:

1 July 2020

 

f)

Place of the transaction:

Off market

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCFFFEIRLIIVII
Date   Source Headline
14th Oct 20215:46 pmRNSIssue of new shares under the SIP
14th Oct 20217:00 amRNSSale of Pentana Compliance
11th Oct 20212:25 pmRNSNotice of AGM
1st Oct 20213:15 pmRNSTotal Voting Rights
1st Oct 20217:00 amRNSChange of Auditor
24th Sep 20219:37 amRNSIssue of Shares, PDMR Dealing & TVR
13th Sep 20214:50 pmRNSExercise of Options and Total Voting Rights
10th Sep 20216:05 pmRNSHolding(s) in Company
2nd Sep 20217:00 amRNSTotal Voting Rights
31st Aug 20219:32 amRNSHolding(s) in Company
26th Aug 20217:00 amRNSPDMR Dealing and Total Voting Rights
11th Aug 20212:02 pmRNSIssue of new shares under the SIP and TVR
11th Aug 20217:00 amRNSExercise of Options and Total Voting Rights
23rd Jul 20214:54 pmRNSPDMR Dealing and Total Voting Rights
22nd Jul 20217:00 amRNSFinal Results
20th Jul 20212:03 pmRNSIssue of new shares under the SIP
19th Jul 20217:00 amRNSTwo highly complementary strategic acquisitions
15th Jul 20214:17 pmRNSExercise of share options and Total Voting Rights
16th Jun 20217:00 amRNSIssue of new shares under the SIP
10th Jun 20214:41 pmRNSSecond Price Monitoring Extn
10th Jun 20214:36 pmRNSPrice Monitoring Extension
21st May 20217:00 amRNSDirector/PDMR Shareholding
13th May 20217:00 amRNSPre-Close Trading Update and Board Change
28th Apr 20217:00 amRNSDirector Dealings and Total Voting Rights
14th Apr 202112:40 pmRNSIssue of Shares, PDMR Dealing & TVR
16th Mar 20213:33 pmRNSIssue of new shares under the SIP and TVR
9th Mar 20217:00 amRNSAcquisition of Qualtrax
26th Feb 20211:49 pmRNSHolding(s) in Company
25th Feb 20214:00 pmRNSHolding(s) in Company
25th Feb 20217:00 amRNSHolding(s) in Company
23rd Feb 20217:00 amRNSPDMR Dealing and Total Voting Rights
16th Feb 20215:15 pmRNSIssue of Equity & Total Voting Rights
12th Feb 20217:00 amRNSDirector/PDMR Dealings
3rd Feb 20219:35 amRNSExtension to 2018 LTIP Awards
26th Jan 20217:00 amRNSSuccession of Chairman
26th Jan 20217:00 amRNSUnaudited Interim Results
25th Jan 20214:26 pmRNSH1 Results Presentation
22nd Jan 20217:00 amRNSHolding(s) in Company
31st Dec 20207:00 amRNSHolding(s) in Company
31st Dec 20207:00 amRNSHolding(s) in Company
30th Dec 20207:21 amRNSCompletion of Huddle Acquisition
23rd Dec 202011:30 amRNSAcquisition of Huddle
22nd Dec 20202:04 pmRNSHolding(s) in Company
18th Dec 202012:56 pmRNSIssue of Shares & Director/PDMR Shareholding
9th Dec 20207:00 amRNSResult of Placing and PrimaryBid Offer
8th Dec 20204:53 pmRNSPrimaryBid.com Offer
8th Dec 20204:50 pmRNSProposed Fundraise of £48.7 million
20th Nov 20203:40 pmRNSIssue of Equity, PDMR Dealing and TVR
17th Nov 202012:05 pmRNSChange of Registered Office
13th Nov 20203:51 pmRNSPDMR Shareholding and Exercise of Options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.